# Vorasidenib clinical development and recognition

> Developing situation record from CLSTR: https://clstr.news/situations/vorasidenib-clinical-development-and-recognition
> Updated: 2026-11-04T10:59:20.000Z. Sources: 5. Developments: 2.

Clinical research presented at the European Association of Neuro-Oncology congress in Rome indicated that vorasidenib achieved disease control in 96% of patients with grade 2 gliomas. This study, conducted across seven hospitals in Andalusia, analyzed 58 patients treated between 2024 and 2025. The drug targets mutated IDH1 and IDH2 enzymes, with the studied group showing a median overall survival of approximately 13 years.

Following these developments, Servier Group Italy received the Prix Galien Italia 2026 in the ‘Neurosciences and Psychopharmacology’ category for the therapy. Vorasidenib is recognized as the first and only oral targeted monotherapy for grade 2 astrocytoma or oligodendroglioma in patients with specific IDH1 or IDH2 mutations. In Italy, the Italian Medicines Agency approved reimbursement for the medication on October 15.

## Claims

- Servier Group Italy won the Prix Galien Italia 2026 in the ‘Neurosciences and Psychopharmacology’ category. (reported by 4 sources)
- Vorasidenib is the first and only oral targeted therapy indicated for monotherapy to treat grade 2 astrocytoma or oligodendroglioma with IDH1 R132 or IDH2 R172 mutations. (reported by 4 sources)
- Vorasidenib is indicated for patients aged 12 and older weighing 40 kg or more. (reported by 4 sources)
- Vorasidenib inhibits mutated IDH1 and IDH2 enzymes to reduce 2-HG production. (reported by 4 sources)
- The Italian Medicines Agency (AIFA) Board of Directors approved reimbursement for vorasidenib on October 15. (reported by 4 sources)

## Timeline

### 2026-11-04: Servier receives Prix Galien Italia for vorasidenib glioma therapy

Servier's vorasidenib won the Prix Galien Italia 2026 for its role as the first oral targeted therapy for specific grade 2 gliomas.

5 sources. https://clstr.news/cluster/servier-receives-prix-galien-italia-for-vorasidenib-glioma-therapy

### 2026-10-06: Vorasidenib treatment shows 96% disease control in grade 2 glioma study

A study presented at the EANO congress shows vorasidenib controlled disease in 96% of grade 2 glioma patients by targeting IDH1 and IDH2 mutations.

2 sources. https://clstr.news/cluster/vorasidenib-treatment-shows-96-disease-control-in-grade-2-glioma-study

---
Cite as: Vorasidenib clinical development and recognition. CLSTR, https://clstr.news/situations/vorasidenib-clinical-development-and-recognition